HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Miller, J. P. Articles by Crawford, L. E. M. Search for Related Content PubMed PubMed Citation Articles by Miller, J. P. Articles by Crawford, L. E. M.

Internal Dosimetry Studies of Radiopharmaceuticals; I. Tolpovidone ¹³¹I¹

North Chicago, Ill.

ABSTRACT

The distribution and effective half-life of Tolpovidone ¹³¹I (¹³¹ Raovin) has been studied in both rats and cats. These data have been extrapolated to man to estimate the radiation dose delivered during the use of ¹³¹Raovin for brain-scanning and diagnosis of hypoalbuminemia. Radiation dosage calculations indicate that a 30 µc dose of Tolpovidone ¹³¹I delivers considerably less radiation than maximum permissible quarterly occupational exposure limits and that a 500 µc dose of Tolpovidone ¹³¹I delivers less radiation than established yearly exposure limits.

FOOTNOTES

¹ Raovin®-131, Abbott Laboratories, North Chicago, Illinois and Oak Ridge, Tennessee. This product is a purified copolymer having an average molecular weight approximating 40,000 and consisting of vinylpyrrolidone and a fixed ratio of p-toluidine. Carrier-free Na¹³I is reacted chemically with this purified material to form a stable bond between the ¹³¹I and the copolymer.

² Nucleonics Laboratory, Abbott Laboratories.